Introduction {#sec1}
============

Pre-eclampsia (PE), a common pregnancy disease diagnosed by hypertension and proteinuria, occurs in approximately 2--8% of pregnancies \[[@B1],[@B2]\]. PE is an important reason for the maternal and fetal morbidity and mortality due to dysfunction of multiple systems and organs, such as liver, kidney and brain \[[@B3]\]. Although its etiology has not been well recognized, PE is now regarded as the result of the combined effect of multiple factors \[[@B4],[@B5]\]. According to the results of the several epidemiological studies, PE has a substantial heritable component, which is estimated to be a major effect \[[@B4],[@B6]\].

The vascular endothelial growth factor (VEGF) gene, located on chromosome 6p21.3, is a key regulator of angiogenesis and vascular function. Therefore, VEGF is vital for the formation of trophoblasts, embryonic vasculature and maternal and foetal blood cells *in utero* \[[@B7]\]. Abnormal vascular growth and endothelial dysfunction have been proposed to be the part of pathogenesis. Hence, VEGF has drawn the attention of many researchers \[[@B8],[@B9]\].

The associations between polymorphisms of the VEGF gene and PE have been extensively studied \[[@B10]\]. However, the results were somewhat controversial. In 2013, two meta-analyses assessed the associations among four polymorphisms of the VEGF gene and the risk of PE \[[@B31],[@B32]\]. But the retrieved datasets of these two meta-analyses were not sufficient, and several new studies have been published regarding this relationship between VEGF gene polymorphisms (rs3025039, rs2010963) and PE \[[@B10]\]. In addition, the results published recently remained inconsistent and conflicting, likely owing to heterogeneity of different researches or inadequate sample size. A comprehensive retrieval of the pertinent literature in multiple databases is likely to help assess disease risks more precisely. In view of the mortality of PE, more efficient biomarkers are required for early discovery and prevention in the clinical practice. Therefore, we performed an updated meta-analysis of all eligible studies including English and non-English journals to investigate the association between VEGF gene polymorphisms and the risk of PE. Moreover, we further divided the cases by ethnic groups, countries as well as genotyping methods and analyzed subgroup specific associations.

Methods {#sec2}
=======

Identification of literature {#sec2-1}
----------------------------

This meta‐analysis was conducted in accordance with the guidance of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement \[[@B33]\]. The PRISMA Checklist was presented in Supplementary Table S1. The literature search using the electronic databases PubMed, EMBASE, Web of Science, Chinese National Knowledge Infrastructure (CNKI) and WanFang was conducted by two study investigators. The comprehensive search strategies included the Mesh term and Keywords: ('vascular endothelial growth factor' or 'VEGF'), ('polymorphism', 'SNP' 'variant', 'genotype' or 'mutations'), ('Pre-eclampsia', 'Preeclampsia', 'Pregnancy Toxemias', 'Pregnancy Toxemia', 'Edema-Proteinuria-Hypertension Gestosis', 'Edema Proteinuria Hypertension Gestosis', 'EPH Complex', 'EPH Toxemias', 'EPH Toxemia', 'Proteinuria-Edema-Hypertension Gestosis' or 'Proteinuria Edema Hypertension Gestosis') through 3 January 2019. All eligible studies were retrieved and examined carefully. Review articles and references of other relevant researches were further searched to find additional eligible studies.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The inclusion criteria were as follows: (i) studies which estimated the associations between VEGF rs2010963 or rs3025039 and the susceptibility to PE; (ii) case--control studies or cohort studies of PE; (iii) patients must be clinically diagnosed for PE (blood pressure ≥ 140/90 mmHg on two measurements with ≥1+ proteinuria or 300 mg/24 h after the 20th week of pregnancy); (iv) reported the allele frequencies of both cases and controls for different genotypes; (v) genotype distribution in the control group confirmed by Hardy--Weinberg equilibrium (HWE). The exclusion criteria of the meta-analysis were: (i) non-human studies, meta-analysis, comments, letters, reviews, mechanism studies or studies without controls, (ii) studies with overlapping or incomplete data. When overlapped population between studies was identified, only the newest or most complete article was included in the analysis. According to the corresponding criteria, two independent authors screened the articles.

Data extraction and assessment of methodological quality {#sec2-3}
--------------------------------------------------------

Data were extracted by two authors independently from each study. The following information was collected: first author, publication year, participants' country, ethnicity (categorized as Caucasian, Xanthoderm, Indo-European hybrid), sample size, study design (case--control or cohort), genotyping method, alleles and genotype frequency distribution in cases and controls, and the major conclusion of the study. When incomplete or apparent conflicting data were found in the article, we made an attempt to contact authors. Inconsistencies in data interpretation were resolved with discussion. The Newcastle--Ottawa Quality Assessment Scale (NOS) was employed to evaluate the methodological quality of the identified articles, and scores ranging from 0 (the worst) to 9 (the best) were assigned based on the quality of the studies. The studies with no less than 5 stars were considered to be of high quality.

Statistical analysis {#sec2-4}
--------------------

First, deviation from HWE in the distribution of allele frequencies was estimated again by the chi-square test (determined by *P*\<0.05). Stata 12.0 was used to perform quantitative meta-analysis. The association was estimated with four models: Allele comparison model, Dominant model, Recessive model and Homozygote model. The four models of the data analysis were conducted by the random-effects model to prevent exaggerated results. The association between the VEGF rs3025039 or rs2010963 and PE risk was assessed by the raw odds ratios (ORs) with 95% confidence intervals (CIs). The Student's *t* test was used to determine the significance of the crude OR, and *P*\<0.05 was considered statistically significant. In addition, heterogeneity assumption among the included researches was evaluated by the Chi-square and *I^2^*, which was regarded to be statistically significant if *P*\<0.10. And *I^2^* values of 25, 50 and 75% were nominally assigned as low, moderate and high estimates. To insure that any single study did not cause an obvious influence to the whole effects, sensitivity analysis was performed to estimate the validity and stability of the study. In addition, to further analyze the source of the heterogeneity and the specific association between the VEGF polymorphism and PE, studies were also divided into several subgroups on the basis of the country, the ethnicity of the related population and the genotyping method. Egger's test was performed to estimate the potential publication bias.

Results {#sec3}
=======

Study characteristics {#sec3-1}
---------------------

As shown in [Figure 1](#F1){ref-type="fig"}, the PRISMA flowchart demonstrated process of the literature retrieval. Four hundred and five studies were identified according to the result of the retrieval strategy and manual searches from PubMed, EMBASE, Web of Science, CNKI and WanFang database. On the basis of our inclusion/exclusion criteria, 142 studies were excluded for duplication and 239 studies were excluded as meta-analysis, reviews, mechanism studies or non-relevant research. Then, 24 studied were selected for full-text review. However, three studies were excluded, because two studies lacked genotype data and one study focused on placental polymorphism. Because most of the studies did not use the rs number to name the SNP, every SNP was manually confirmed by searching in the NCBI according to the sequence in the literature. Finally, 21 studies were included in the meta-analysis. Thereinto, 15 studies assessed the association between VEGF rs3025039 T/C polymorphism and the risk of PE, and 12 studies examined the association between VEGF rs2010963 C/G polymorphism and the risk of PE. The specific information about the included studies was exhibited in [Table 1](#T1){ref-type="table"}. The quality evaluation of each study following the NOS is presented in [Table 2](#T2){ref-type="table"}, which showed all of these studies can be regarded as high-quality studies.

![PRISMA flow chart of selection procedure](bsr-40-bsr20190209-g1){#F1}

###### Study characteristics of PE cases and controls in the analysis of VEGF polymorphisms

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author \[Ref.\]            Year   Country       Ethnicity              Sources of controls   Number   Polymorphism(s)   Genotyping method   Association findings   
  -------------------------- ------ ------------- ---------------------- --------------------- -------- ----------------- ------------------- ---------------------- -------------
  Lu \[[@B10]\]              2017   China         Xanthoderm             HB                    156      286               rs3025039           Snapshot               NS

  Amosco \[[@B11]\]          2016   Philippines   Xanthoderm             HB                    165      191               rs3025039\          MassARRAY system       Supportive\
                                                                                                                          rs2010963                                  NS

  Salimi \[[@B12]\]          2015   Iran          Caucasian              HB                    192      186               rs2010963           PCR-RFLP               Supportive

  Silva \[[@B13]\]           2015   Brazil        Caucasian              HB                    79       210               rs2010963           PCR-RFLP               NS

  Zhang Honghui \[[@B14]\]   2014   China         Xanthoderm             HB                    58       70                rs3025039\          Sequencing             Supportive\
                                                                                                                          rs2010963                                  NS

  Procopciuc \[[@B15]\]      2014   Romania       Caucasian              HB                    70       94                rs3025039           PCR-RFLP               Supportive

  Chedraui \[[@B16]\]        2013   Ecuador       Indo-European hybrid   HB                    31       31                rs3025039\          Sequencing             NS
                                                                                                                          rs2010963                                  

  Andraweere \[[@B17]\]      2013   Australia     Caucasian              HB                    174      168               rs3025039           MassARRAY system       NS

  Atis \[[@B18]\]            2012   Turkey        Caucasian              HB                    34       58                rs3025039           MassARRAY system       NS

  Chen Baoli \[[@B19]\]      2011   China         Xanthoderm             HB                    84       71                rs3025039           PCR-RFLP               Supportive

  He Yun \[[@B20]\]          2011   China         Xanthoderm             HB                    61       43                rs3025039\          Sequencing             Supportive
                                                                                                                          rs2010963                                  

  Garza-Veloz \[[@B21]\]     2011   Mexico        Indo-European hybrid   HB                    86       78                rs2010963           PCR-RFLP               NS

  Cunha \[[@B22]\]           2010   Brazil        Caucasian              HB                    52       28                rs3025039           PCR-RFLP               NS

  Liu Shifang \[[@B23]\]     2010   China         Xanthoderm             HB                    84       71                rs3025039           PCR-RFLP               Supportive

  Huang Yuliang \[[@B24]\]   2009   China         Xanthoderm             HB                    128      231               rs3025039           PCR-RFLP               Supportive

  Sandrim \[[@B25]\]         2008   Brazil        Caucasian              HB                    94       108               rs2010963           TaqMan-assays          NS

  Nagy \[[@B26]\]            2008   Hungary       Caucasian              HB                    71       93                rs2010963           real-time PCR          NS

  Shim \[[@B27]\]            2007   Korea         Xanthoderm             HB                    110      209               rs3025039           PCR-RFLP               Supportive

  Kim \[[@B28]\]             2007   Korea         Xanthoderm             HB                    223      237               rs3025039\          Snapshot               NS
                                                                                                                          rs2010963                                  

  Banyasz \[[@B29]\]         2006   Hungary       Caucasian              HB                    84       96                rs2010963           PCR-RFLP               Supportive

  Papazoglou \[[@B30]\]      2004   Sweden        Caucasian              HB                    42       73                rs3025039\          PCR-RFLP               Supportive\
                                                                                                                          rs2010963                                  NS
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CTR, control; HB: hospital-based study; NS: non-significant.

###### Quality assessment conducted according to the Newcastle--Ottawa Scale for all the included studies

                      Selection   Comparability   Exposure                              
  ------------------- ----------- --------------- ---------- ---- ------ ---- ---- ---- ---
  Lu \[[@B10]\]       \*          \*                         \*          \*   \*   \*   6
  Amosco \[[@B11]\]   \*          \*                         \*   \*     \*   \*   \*   7
  Salimi \[[@B12]\]   \*          \*                         \*   \*     \*   \*   \*   7
  Silva \[[@B13]\]    \*          \*                         \*   \*     \*   \*   \*   7
  Zhang Honghui       \*          \*                         \*          \*   \*        5
  Procopciuc          \*          \*                         \*   \*     \*   \*   \*   7
  Chedraui            \*          \*                         \*   \*     \*   \*   \*   7
  Andraweere          \*          \*                         \*   \*     \*   \*   \*   7
  Atis                \*          \*                         \*   \*     \*   \*   \*   7
  Chen Baoli          \*          \*                         \*          \*   \*        5
  He Yun              \*          \*                         \*          \*   \*   \*   6
  Garza-Veloz         \*          \*                         \*   \*\*   \*   \*   \*   8
  Cunha               \*          \*                         \*   \*     \*   \*   \*   7
  Liu Shifang         \*          \*                         \*   \*     \*   \*        6
  Huang Yuliang       \*          \*                         \*          \*   \*        5
  Sandrim             \*          \*                         \*   \*\*   \*   \*   \*   8
  Nagy                \*          \*                         \*   \*     \*   \*   \*   7
  Shim                \*          \*                         \*   \*\*   \*   \*   \*   8
  Kim                 \*          \*                         \*   \*     \*   \*   \*   7
  Banyasz             \*          \*                         \*   \*\*   \*   \*   \*   8
  Papazoglou          \*          \*                         \*   \*\*   \*   \*   \*   8

Overall analysis {#sec3-2}
----------------

Overall results of this meta-analysis between the two SNP and PE are displayed in [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. In total, we analyzed 1426 cases and 1872 controls for rs3025039 with the random-effect model, showing a significantly increased risk for the comparison of the T allele to the C allele (OR = 1.418, 95% CI = 1.060--1.898, *P*=0.019, [Figure 2](#F2){ref-type="fig"}A). Also, the results of the three genotype models analysis all revealed a significant association between PE and the VEGF rs3025039 (Dominant model: OR = 1.637, 95% CI = 1.031--2.598, *P*=0.037, [Figure 2](#F2){ref-type="fig"}B; Recessive model: OR = 1.501, 95% CI = 1.068--2.109, *P*=0.019, [Figure 2](#F2){ref-type="fig"}C; Homozygote model: OR = 1.819, 95% CI = 1.021--3.240, *P*=0.042, [Figure 2](#F2){ref-type="fig"}D), in which the result of the Recessive model exhibited high heterogeneity (*I^2^* = 77.2%) and others were acceptable. An analysis of 1148 cases and 1388 controls for rs2010963 showed the C allele in allele comparison model, CC and CG genotype in the recessive model and CC genotype in the homozygous model increased the risk of PE significantly (Allele comparison model: OR = 1.207, 95% CI = 1.046--1.394, *P*=0.010, [Figure 3](#F3){ref-type="fig"}A; Recessive model: OR = 1.310, 95% CI = 1.044--1.643, *P*=0.020 [Figure 3](#F3){ref-type="fig"}C; Homozygote model: OR = 1.324, 95% CI = 1.024--1.713, *P*=0.032, [Figure 3](#F3){ref-type="fig"}D), however the result of the dominant model did not indicate statistical significance (OR = 1.154, 95% CI = 0.912--1.460, *P*=0.232, [Figure 3](#F3){ref-type="fig"}B).

![Forest plot of PE risk associated with VEGF gene rs3025039 polymorphism\
(**A**) Allele comparison model. (**B**) Dominant model. (**C**) Recessive model. (**D**) Homozygote model.](bsr-40-bsr20190209-g2){#F2}

![Forest plot of PE risk associated with VEGF gene rs2010963 polymorphism\
(**A**) Allele comparison model. (**B**) Dominant model. (**C**) Recessive model. (**D**) Homozygote model.](bsr-40-bsr20190209-g3){#F3}

###### Main results for the rs3025039 polymorphism with the risk of PE

  Comparison     Subgroup               Number   Test of association   Test of heterogeneity                          
  -------------- ---------------------- -------- --------------------- ----------------------- ------------- -------- ---------
  T vs C         Overall                15       1.418                 1.060--1.898            **0.019**     76.6%    \<0.001
                 China                  6        1.793                 1.229--2.617            **\<0.001**   69.5%    0.006
                 Korea                  2        1.219                 0.438--3.392            0.704         93.3%    \<0.001
                 Other Countries        7        1.189                 0.738--1.917            0.476         73.6%    \<0.001
                 Xanthoderm             9        1.454                 0.995--2.125            **0.053**     83.5%    \<0.001
                 Caucasian              5        1.361                 0.758--2.444            0.301         73.1%    0.005
                 Indo-European hybrid   1        1.369                 0.628--2.984            0.429         /        /
                 MassARRAY system       2        0.681                 0.484--0.958            **0.028**     \<0.1%   0.483
                 Sequencing             2        1.942                 1.182--3.191            **0.009**     20.0%    0.264
                 PCR-RFLP               9        1.961                 1.594--2.413            **\<0.001**   14.1%    0.316
                 Snapshot               2        0.778                 0.601--1.007            0.056         \<0.1%   0.566
  TT vs CC+CT    Overall                14       1.637                 1.031--2.598            **0.037**     22.5%    0.210
                 China                  5        2.420                 1.400--4.180            **0.002**     \<0.1%   0.436
                 Korea                  2        1.514                 0.334--6.873            0.591         73.6%    0.052
                 Other countries        7        1.062                 0.502--2.246            0.911         \<0.1%   0.465
                 Xanthoderm             9        1.795                 0.979--3.291            0.059         42.1%    0.098
                 Caucasian              5        1.144                 0.438--2.987            0.784         1.0%     0.400
                 Indo-European hybrid   1        2.148                 0.364--12.693           0.399         /        /
                 MassARRAY system       2        0.338                 0.091--1.256            0.105         \<0.1%   0.555
                 Sequencing             2        4.378                 1.525--12.572           **0.006**     \<0.1%   0.328
                 PCR-RFLP               8        2.409                 1.399--4.150            **0.002**     \<0.1%   0.980
                 Snapshot               2        0.926                 0.461--1.858            0.828         \<0.1%   0.478
  TT +CT vs CC   Overall                15       1.501                 1.068--2.109            **0.019**     75.1%    \<0.001
                 China                  6        1.933                 1.205--3.102            **0.006**     71.6%    \<0.001
                 Korea                  2        1.243                 0.385--4.019            0.716         92.9%    \<0.001
                 Other countries        7        1.260                 0.724--2.193            0.414         73.6%    \<0.001
                 Xanthoderm             9        1.520                 0.977--2.365            0.063         82.8%    \<0.001
                 Caucasian              5        1.513                 0.769--2.977            0.230         72.9%    0.005
                 Indo-European hybrid   1        1.295                 0.477--3.515            0.612         /        /
                 MassARRAY system       2        0.700                 0.481--1.019            0.063         \<0.1%   0.317
                 Sequencing             2        1.976                 1.035--3.772            **0.039**     12.1%    0.286
                 PCR-RFLP               9        2.186                 1.678--2.848            **\<0.001**   24.0%    0.230
                 Snapshot               2        0.726                 0.540--0.978            **0.035**     \<0.1%   0.697
  TT vs CC       Overall                14       1.819                 1.021--3.240            **0.042**     45.7%    0.032
                 China                  5        3.009                 1.403--6.453            **0.005**     32.3%    0.206
                 Korea                  2        1.658                 0.256--10.750           0.596         82.3%    0.017
                 Other countries        7        1.139                 0.467--2.781            0.775         24.9%    0.239
                 Xanthoderm             9        2.041                 0.958--4.346            0.064         60.6%    0.013
                 Caucasian              5        1.256                 0.376--4.198            0.711         32.2%    0.207
                 Indo-European hybrid   1        2.267                 0.362--14.185           0.382         /        /
                 MassARRAY system       2        0.316                 0.085--1.177            0.086         \<0.1%   0.605
                 Sequencing             2        5.284                 1.322--21.116           **0.019**     33.0%    0.222
                 PCR-RFLP               8        3.120                 1.793--5.429            **\<0.001**   \<0.1%   0.921
                 Snapshot               2        0.846                 0.420--1.707            0.641         \<0.1%   0.462

Presentation with bold indicated a statistical significance.

###### Main results for the rs2010963 polymorphism with the risk of PE

  Comparison     Subgroup               Number   Test of association   Test of heterogeneity                        
  -------------- ---------------------- -------- --------------------- ----------------------- ----------- -------- -------
  C vs G         Overall                12       1.207                 1.046--1.394            **0.010**   26.1%    0.188
                 Xanthoderm             4        1.178                 0.879--1.581            0.273       46.1%    0.135
                 Caucasian              6        1.246                 1.004--1.546            **0.046**   38.4%    0.150
                 Indo-European hybrid   2        1.199                 0.817--1.760            0.353       \<0.1%   0.417
                 Sequencing             2        1.620                 1.044--2.516            **0.032**   \<0.1%   0.940
                 PCR-RFLP               6        1.149                 0.971--1.358            0.105       \<0.1%   0.640
                 Other methods          4        1.224                 0.866--1.731            0.253       68.1%    0.024
  CC vs GG+GC    Overall                12       1.154                 0.912--1.460            0.232       \<0.1%   0.647
                 Xanthoderm             4        0.932                 0.626--1.387            0.729       \<0.1%   0.510
                 Caucasian              6        1.295                 0.948--1.768            0.104       \<0.1%   0.462
                 Indo-European hybrid   2        1.296                 0.564--2.975            0.541       \<0.1%   0.784
                 Sequencing             2        0.974                 0.314--3.020            0.964       \<0.1%   0.976
                 PCR-RFLP               6        1.231                 0.896--1.690            0.200       \<0.1%   0.689
                 Other methods          4        1.203                 0.676--2.142            0.529       43.2%    0.152
  CC +GC vs GG   Overall                12       1.310                 1.044--1.643            **0.020**   42.6%    0.058
                 Xanthoderm             4        1.350                 0.898--2.031            0.149       52.3%    0.098
                 Caucasian              6        1.278                 0.894--1.826            0.178       56.0%    0.045
                 Indo-European hybrid   2        1.360                 0.667--2.772            0.397       33.4%    0.221
                 Sequencing             2        2.328                 1.294--4.189            **0.005**   \<0.1%   0.901
                 PCR-RFLP               6        1.174                 0.924--1.491            0.189       \<0.1%   0.663
                 Other methods          4        1.322                 0.804--2.175            0.272       73.8%    0.010
  CC vs GG       Overall                12       1.324                 1.024--1.713            **0.032**   \<0.1%   0.622
                 Xanthoderm             4        1.134                 0.734--1.753            0.570       \<0.1%   0.433
                 Caucasian              6        1.461                 1.019--2.094            **0.039**   8.9%     0.359
                 Indo-European hybrid   2        1.377                 0.557--3.406            0.489       \<0.1%   0.905
                 Sequencing             2        1.555                 0.479--5.048            0.462       \<0.1%   0.994
                 PCR-RFLP               6        1.287                 0.907--1.827            0.157       \<0.1%   0.699
                 Other methods          4        1.469                 0.771--2.799            0.242       49.0%    0.117

Presentation with bold indicated a statistical significance.

Subgroup analyses {#sec3-3}
-----------------

The subgroup analyses were carried out due to the heterogeneity of result and biases of the different subgroups. The results of subgroup analyses were shown in [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. First of all, the different countries of population were divided into three parts including China, Korea and other countries in rs3025039 according to the source of the population in studies. For countries subgroup analyses in rs3025039 polymorphism, a significant correlation was found in the allele model and the three genotype models of the Chinese subgroup, in which the Allele comparison model showed moderate heterogeneity (*I^2^* = 69.5%), the Dominant model showed low heterogeneity (*I^2^* \< 0.001%), the Recessive model showed high heterogeneity (*I^2^* = 71.6%) and the Homozygote model showed moderate heterogeneity (*I^2^* = 32.3%). However, no significant association was found in the Korea's subgroup and other countries' subgroup, and relatively high heterogeneity was observed in the almost all models of the two subgroups except in Dominant and Homozygote model of other countries' subgroup, which indicated the differences of population countries were not the major cause of the heterogeneity for rs3025039 in this meta-analysis. Then, we performed an ethnic restriction including Xanthoderm, Caucasian and Indo-European hybrid for further subgroup analysis in rs3025039. No significant association was observed in the any model, and the heterogeneity of various models in different subgroups showed no significant reduction. Next, subgroup analysis was performed in rs3025039 according to the genotyping methods including MassARRAY system, Sequencing, PCR-RFLP and Snapshot. A significantly increased risk was found in the Sequencing and PCR-RFLP subgroup, but a protective effect was found in the MassARRAY system subgroup with Allele comparison model and Snapshot subgroup with Recessive model. The heterogeneity of all the subgroup in the four models were relatively low, which indicated that the genotyping methods might be the major source of the heterogeneity.

For rs2010963, we performed the subgroup analysis based on ethnicity and genotyping methods, because the overlapping countries were limited. The subgroups of ethnicity were divided as the same as the subgroups of rs3025039. A significant association was observed in the Caucasian subgroup with both Allele comparison model and Homozygote model (Allele comparison model: OR = 1.246, *P*=0.046; Homozygote model: OR = 1.461, *P*=0.039), and other subgroups showed no obvious difference. Moreover, the heterogeneity of allele comparison model and homozygote model in Caucasian subgroup was low (Allele comparison model: *I^2^* = 38.4%, Homozygote model: *I^2^* = 8.9%). However, the difference between the overall heterogeneity and subgroup heterogeneity was not apparent, illustrating that the ethnicity was not the important cause of heterogeneity in the meta-analysis. Regarding the genotyping methods subgroups, we divided into three groups: Sequencing, PCR-RFLP and other methods, owing to the duplicating number of the genotyping methods. The result of the Sequencing subgroup showed a statistically significant in Allele comparison model and Homozygote model with indistinctive heterogeneity (Allele comparison model: OR = 1.620, *P*=0.032, *I^2^* \< 0.1%; Recessive model: OR = 2.328, *P*=0.005, *I^2^* \< 0.1%). Besides, heterogeneity of the Sequencing and PCR-RFLP subgroups in all models was not significant (*I^2^* \< 0.1%), while heterogeneity of other methods subgroups was higher. The results suggested that the source of the heterogeneity might be the genotyping methods, consistent with the conclusion above.

Sensitivity analysis and publication bias {#sec3-4}
-----------------------------------------

To confirm the reliability of our results, a sensitivity analysis was performed for the allele model, showing no apparent difference before and after the removal of each study shown in [Figure 4](#F4){ref-type="fig"}. In addition, publication bias assessed by Egger's regression test present no obvious evidence in statistics, which was displayed in [Table 5](#T5){ref-type="table"}.

![Sensitive analyses of individual study for VEGF gene polymorphisms\
(**A**) rs3025039 polymorphism. (**B**) rs2010963 polymorphism.](bsr-40-bsr20190209-g4){#F4}

###### Egger's regression test of the two VEGF polymorphisms

                             rs3025039         rs2010963                                                                                                  
  -------------- ----------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ---------------- ----------------
  Egger's test   *P-*value   0.319             0.678             0.126             0.847             0.182             0.153             0.518            0.227
                 95% CI      \[−2.12, 6.02\]   \[−2.05, 1.38\]   \[−0.91, 6.60\]   \[−2.26, 1.88\]   \[−0.88, 4.05\]   \[−0.43, 2.40\]   \[−2.30 4.27\]   \[−0.67 2.50\]

Discussion {#sec4}
==========

Although the etiology of PE is considered to be multifactorial, genetic factors are thought to be strong determinants of this disease \[[@B4],[@B6]\]. Early studies reported that VEGF genes were associated with vascular growth and endothelial dysfunction, which may somewhat interpret the development of PE. In recent decades, many researchers have been focusing on the role that VEGF gene may play in the cause of PE \[[@B34]\]. However, case--control studies have shown contradictory associations between VEGF gene polymorphisms and PE. The aim of this meta-analysis was to evaluate the association between VEGF rs3025039 and rs2010963 polymorphisms and PE for the use of the biomarkers in the clinical practice and the investigation of the concrete pathomachanism.

We conducted a thorough literature retrieve and review to identify as many relevant studies as possible in our meta-analysis. Compared with previous meta-analyses, we made an effort to gain some improvements in our analysis: first, several studies were not included in previous meta-analyses (Lum (2017), Amosco et al. (2016), Salimi et al. (2015), Silva et al. (2014), Zhang Honghui et al. (2014), Procopciuc et al. (2014), Atis et al. (2012), Chen Baoli et al. (2011), Liu Shifang (2010)); second, multiple subgroups were divided to be analyzed; thereby a more adequate statistical power was gained in our study. Similar to the published researches, we found significant associations between the two VEGF gene polymorphisms (rs3025039, rs2010963) and PE, suggesting VEGF gene variants in rs3025039 and rs2010963 loci might be involved in the development of PE. Our results provide evidence of a significantly increased risk about rs3025039 polymorphisms for PE with the four models. Compared with the previous meta-analyses, a significantly increased risk for PE was observed in rs2010963 polymorphisms with less heterogeneity except for the Dominant model. In the stratified analysis by ethnicity and countries for rs3025039, a significantly increased risk of pre-eclampsia was observed in studies conducted among Chinese population. As for subgroup analyses of ethnicity in rs2010963, a statistically association was found in the Allele comparison and the Homozygote models of Caucasian.

In addition, the heterogeneity could be accounted for by the subgroup analysis of genotyping methods. For rs3025039 polymorphism, the subgroup analyses of four genotyping methods including MassARRAY system, Sequencing, PCR-RFLP and Snapshot all showed low levels of heterogeneity (*I^2^* \< 40%, *P*\>0.10), where the results of the PCR-RFLP and Sequencing were consistent with the total result (OR \> 1, *P*\<0.05), but different from the result of the other genotyping methods. Similarly, the heterogeneity of the three subgroups covering PCR-RFLP and Sequencing and other methods was different for rs2010963 polymorphism. The heterogeneity of the PCR-RFLP and Sequencing subgroup was quite low (*I^2^* \< 10%, *P*\>0.1), whereas the heterogeneity of the other methods subgroup was extensive (*I^2^* \> 40%). The reason could be that studies in each subgroup are relatively few or different genotyping methods may influence the genotyping result. This observation is similar to previous studies, in which differences in genotyping methods might contribute to heterogeneity \[[@B35],[@B36]\]. The results would be more reliable and accurate if the same appropriate genotyping method was applied in different studies, because different genotyping methods have specialty in different aspects. Genotyping results with new genotyping technologies need to be confirmed using direct sequencing. Furthermore, we have made efforts to seek out the potential sources of heterogeneity via sensitivity analysis assess and publication biases assessment through Egger's test, demonstrating impact of the individual literature and the publication biases were not obvious. Although the exact pathogenesis of how the SNPs change VEGF and PE susceptibility are not fully understood, a significant correlation between VEGF SNPs (rs3025039 and rs2010963) and PE have been confirmed by our present meta-analysis. At present, several biomarkers have been associated with PE, including soluble endoglin, Flt-1, MAP, PlGF and so on \[[@B37]\]. Integration of more reliable biomarkers and figuring out the feasibility in different ethnical groups will increase the accuracy the prediction of the PE, which is quite important for the early prevention of PE. In the present study, our results provide the evidence that the status of the VEGF is close to occurrence of PE and the two SNPs of the VEGF could be applied in prediction of PE, particularly different ethnical groups.

Several limitations of our meta-analysis should be acknowledged. First, unpublished reports or studies published in other non-international journals could not be included in the analysis. These problems may have affected the stability of the meta-analysis data. Secondthe pooled sample sizes for the subgroup analyses among Xanthoderm and Caucasian for both rs2010963, rs3025039 were relatively small (\<2000 for cases), which may limit the statistical power. Third, the recruitment criteria of patients and controls varied in different studies. Finally, gene--gene or gene--environment interactions were not considered in the present study---such as age, smoking, alcohol status and mental state---which may have influenced the associations between VEGF gene polymorphisms and PE risk. Nevertheless, this meta-analysis improves our understanding of the associations between two polymorphisms of VEGF gene and the risk of PE.

In conclusion, the two VEGF gene polymorphisms are associated with an increased risk of pre-eclampsia in different ethnic groups, respectively. A large number of and high-quality studies are required to establish more precise evidence and minimize the bias in meta-analysis.
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